Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas

Not Applicable

Not yet recruiting

• Conditions: Cutaneous Lymphoma
• Interventions: Other: Biologic Samples

• Registration Number: NCT04520529
• Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Brief Summary

Cutaneous lymphomas are a heterogeneous group of extra-nodal lymphomas. The prognosis of cutaneous lymphomas is extremely variable from one subject to another. In the majority of cases, there is no cure for cutaneous lymphomas. Cutaneous lymphomas primarily affect the skin, and secondarily the blood, lymph nodes and possibly other organs. The discovery of new molecular prognostic factors will allow a better identification of patients at high risk of aggressive evolution and the implementation of a personalized therapeutic strategy. The identification of new therapeutic targets is necessary in order to develop new innovative treatments for cutaneous lymphomas.The primary objective is to identify novel molecular prognostic factors associated with 5-year overall survival in cutaneous lymphoma.

Detailed Description

Not available

Study Timeline

• Status Verified: 2020-08
• Study First Submitted: 2020-08-17
• Study First Submitted QC: 2020-08-17
• Last Update Submitted: 2020-08-17
• Study First Posted: 2020-08-20
• Last Update Posted: 2020-08-20
• Study Start: 2020-09-30
• Primary Completion: 2045-09-30
• Study Completion: 2050-09-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• Age> 18 years old
• Informed consent signed by the patient
• Suspicion of primary cutaneous lymphoma or confirmed lymphoma according to WHO/ISCL/EORTC criteria

Exclusion Criteria

• Patient under guardianship or curatorship
• Lack of affiliation to social security

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Patients with primary cutaneous lymphoma	Biologic Samples	-

Primary Outcome Measures

Name	Time	Method
overall survival	5 years

Secondary Outcome Measures

Name	Time	Method
Overall survival	10 years
Progression free survival	10 years